Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Long-Term Deferred Tax (2022 - 2025)

Ascentage Pharma Group International posted quarterly Long-Term Deferred Tax of $6.3 million for Q4 2025, up 2.5% year-on-year from $6.2 million in Q4 2024, and up 35.46% on a QoQ basis from $4.7 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 4 years of Long-Term Deferred Tax data on file, last reported at $6.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 2.5% year-over-year to $6.3 million; the trailing twelve-month figure through Dec 2025 stood at $6.3 million (up 2.5% YoY), and the FY2025 full-year result was $4.6 million, down 24.59% from the prior year.
  • Long-Term Deferred Tax for Q4 2025 stood at $6.3 million, up from $4.7 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $155.5 million in Q4 2023 and bottomed at $4.7 million in Q2 2025.
  • The 4-year median for Long-Term Deferred Tax is $6.3 million (2025), against an average of $36.2 million.
  • The widest annual swing landed in 2023, when Long-Term Deferred Tax surged 1755.42%; it then slumped 96.04% in 2024.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $8.4 million in 2022, then soared by 1755.42% to $155.5 million in 2023, then plunged by 96.04% to $6.2 million in 2024, then climbed by 2.5% to $6.3 million in 2025.
  • The last three Long-Term Deferred Tax figures came in at $6.3 million (Q4 2025), $4.7 million (Q2 2025), and $6.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 6.31 Mn
Jun 30, 2025 4.66 Mn
Dec 31, 2024 6.16 Mn
Dec 31, 2023 155.54 Mn
Dec 31, 2022 8.38 Mn